Redmile Group LLC acquired a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 552,506 shares of the company’s stock, valued at approximately $36,576,000. Keros Therapeutics comprises approximately 1.3% of Redmile Group LLC’s investment portfolio, making the stock its 29th biggest holding. Redmile Group LLC owned approximately 1.53% of Keros Therapeutics as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also made changes to their positions in the company. ADAR1 Capital Management LLC purchased a new position in Keros Therapeutics during the 4th quarter worth approximately $27,367,000. Darwin Global Management Ltd. boosted its holdings in Keros Therapeutics by 35.4% in the 1st quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company’s stock valued at $95,060,000 after purchasing an additional 375,523 shares in the last quarter. Franklin Resources Inc. increased its position in Keros Therapeutics by 47.9% during the 4th quarter. Franklin Resources Inc. now owns 699,425 shares of the company’s stock worth $27,809,000 after purchasing an additional 226,674 shares during the period. Vanguard Group Inc. raised its stake in shares of Keros Therapeutics by 18.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,406,431 shares of the company’s stock worth $44,837,000 after buying an additional 222,652 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Keros Therapeutics by 17.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock valued at $80,666,000 after buying an additional 176,803 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.
Keros Therapeutics Price Performance
Keros Therapeutics stock traded down $0.29 during trading hours on Monday, hitting $52.03. The stock had a trading volume of 518,449 shares, compared to its average volume of 387,773. Keros Therapeutics, Inc. has a 1-year low of $27.02 and a 1-year high of $73.00. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -10.10 and a beta of 1.23. The stock’s fifty day moving average is $47.34 and its two-hundred day moving average is $55.45.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on KROS. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a report on Tuesday, June 18th. Truist Financial reiterated a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a report on Tuesday, June 18th. Finally, Oppenheimer began coverage on shares of Keros Therapeutics in a research note on Tuesday, June 25th. They issued an “outperform” rating and a $102.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $92.17.
Read Our Latest Analysis on Keros Therapeutics
About Keros Therapeutics
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Featured Stories
- Five stocks we like better than Keros Therapeutics
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Survey: Top 175 Fittest Retirement Locations in America
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Using the MarketBeat Stock Split Calculator
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.